Drugs / JANX014
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07545811 | Apr 2026 → May 2028 expected | castration-resistant prostate carcinoma | Janux Therapeutics | Recruiting | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2026-04-16 | Janux Therapeutics | Janux Therapeutics Announces First Participant Dosed in Phase 1 Study of JANX014 januxrx.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JANX014 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07545811 ↗ |
| Route | Intravenous | “via IV dosing” NCT07545811 ↗ |